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ABSTRACT 
 
OBJECTIVE: The objective of this systematic review is to determine whether or not maternal 
buprenorphine use during pregnancy is effective in preventing neonatal abstinence syndrome 
(NAS). 
 
STUDY DESIGN: Review of three English language primary studies published in 2005, 2006 
and 2008. 
 
DATA SOURCES: Two randomized, double blind (with flexible dosing) trials and one case 
series comparing methadone maintenance and buprenorphine maintenance during pregnancy 
were found using Ovid MEDLINE and CINAHL databases. 
 
OUTCOME MEASURED: Incidence of neonates requiring treatment for NAS and amount of 
medication used, total length of hospital stay and peak NAS scores using the Finnegan Scale and 
a modified 19 item Finnegan Scale.  The Finnegan Scale assess infants for the most common 
signs and symptoms of neonatal withdrawal including: High pitched cry, restlessness, 
hyperactive moro reflex, tremors, increased muscle tone, excoriation, myoclonic jerks, 
convulsions, sweating, fever, yawning, mottling, nasal stuffiness, sneezing, nasal flaring, 
increased respiratory rate, excessive sucking, poor feeding, regurgitation/vomiting, lose/watery 
stools.   
 
RESULTS: The two RCTs included in this review did not find maternal buprenorphine use to be 
effective in preventing NAS.  The case series included did find a significant relationship between 
maternal buprenorphine use and a reduction in NAS symptoms. 
 
CONCLUSIONS: The results of the two RCTs demonstrate that maternal buprenorphine use is 
not effective in preventing NAS symptoms.  The case series did find a significant relationship, 
however because of the nature of the study (case series) the results must be interpreted with 
caution and additional RCTs are needed to evaluate the effectiveness of maternal buprenorphine 
use and NAS. 
 
KEY WORDS: Neonatal abstinence syndrome, withdrawal, buprenorphine, methadone, 
pregnancy. 
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INTRODUCTION 
 Illicit drug use among pregnant women is on the rise, resulting in over 225,000 infants in 
the past year to be exposed to illegal substances prenatally
1
.  Neonates exposed to illicit drugs 
are at greater risk of developing neonatal abstinence syndrome (NAS) as an astounding 50%-
95% of infants exposed to heroin in utero will exhibit signs and symptoms of NAS
2
. While NAS 
is becoming more prevalent, there remains controversy regarding the most effective way to 
prevent and treat this illness.   
 Approximately 5.2% of pregnant women and 9.2% of non-pregnant women report past-
month illicit drug use
1 
making maternal substance abuse and NAS an all too relevant topic in 
medicine today.  The prevalence of opioid use during pregnancy ranges from 1-21% of women
2
.  
While an exact cost of treating NAS has not been identified, neonatal withdrawal results in 
longer hospital stays and ultimately increased costs as 60-80% of all infants exposed to 
methadone will present with some symptoms of NAS
6
. 
 Neonatal withdrawal can occur when a fetus is exposed to a variety of illicit drugs or 
medications such as opiates, tobacco, alcohol and sedatives.  Signs and symptoms of NAS are 
generally seen within 2-3 days of birth, but may not present for up to one month
1
.  Infants are 
evaluated using the Finnegan Scale, a standardized scoring system that identifies 21 signs and 
symptoms of withdrawal, such as decreased sleep, tremors, excessive suck, sweating and loose 
stools
3,4,5
. 
 NAS is generally treated using diluted tincture of opium (DTO)
1
, however methadone 
and morphine are alternatives.  In addition to DTO, oral Phenobarbital is often used adjunctively.  
While these treatments are effective, more information is needed regarding the prevention of 
NAS.  Methadone is the only recommended treatment for opiate dependence in pregnant women, 
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however over half of methadone exposed infants require treatment for NAS
1
.  Buprenorphine, an 
opioid substitute that has both mixed agonist and antagonist properties may provide an 
alternative to methadone in pregnant patients.  Because buprenorphine has high opioid receptor 
affinity and low intrinsic activity adults experience fewer signs and symptoms of withdrawal 
upon discontinuation, it is theorized that infants exposed to buprenorphine in utero may 
experience fewer signs and symptoms of withdrawal when compared to methadone.
1
. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not maternal 
buprenorphine use during pregnancy is effective in preventing neonatal abstinence syndrome. 
METHODS 
Included in this analysis were two randomized controlled trials (RCTs) and a case series, 
all of which compared maternal buprenorphine use to methadone.  The criteria used to select 
each study included pregnant women who were at least 18 years of age
3
 or between the ages of 
21-43
4,5
 that met the DSM-IV criteria for opioid dependence.  The intervention used was 
sublingual buprenorphine 4-24 mg.  Comparison to this intervention was oral methadone HCL 
20-100 mg.  To assess outcomes a variety of methods were used including the Finnegan Scale 
and modified Finnegan Scale to assess for signs and symptoms of NAS, need for pharmacologic 
intervention and length of neonatal hospital stay.   
 A detailed inquiry was performed by the author using the search engines OVID Medline 
and CINAHL.  The key words “Neonatal abstinence syndrome”, “Buprenorphine” and 
“Pregnancy” were used in combination to search for articles.  The articles chosen were published 
in English and in peer-reviewed journals from 2005-2008.  Articles were selected based on their 
relevance and the importance of outcomes to the patient (Patient Oriented Evidence that Matters, 
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or POEMS).  Studies included in this review were two randomized, prospective, controlled, 
double blind/double dummy and one case series, all of which included patient oriented 
outcomes.  Table 1 includes the demographics of the included studies.  Studies that were 
excluded included those that used combination treatment with buprenorphine or methadone and 
those with participants under the age of 18. The statistics utilized in the studies were relative risk 
reduction (RRR), absolute risk reduction (ARR), numbers needed to treat (NNT) and p-value. 
OUTCOMES MEASURED 
 The primary outcome measured in all three studies was the severity of neonatal 
withdrawal using either the Finnegan scale
3,6  
or modified 19-Item Finnegan scale
5
.  The 
Finnegan scale is a 21 item standardized scoring system that assess for signs and symptoms of 
opioid withdrawal in neonates
4
.  The Finnegan scale includes the following signs and symptoms 
of withdrawal: Increased/high pitched cry, decreased sleep, hyperactive moro-reflex, tremors 
(disturbed and undisturbed), increased muscle tone, excoriation, myoclonic jerks, convulsions, 
mottling, nasal stuffiness, nasal flaring, sweating, fever, increased respiratory rate, excessive 
suck, regurgitation/vomiting, poor feeding and loose/watery stools
4
.  Jones et al utilized a 
modified Finnegan scale that did not include myoclonic jerks, mottling and excessive suck as 
part of the evaluation
5
.  Other outcomes measured included the number of infants requiring 
medication management and the total days of neonatal hospital stay 
5,6
.  In addition Jones et al 
included total amount of morphine needed to treat NAS symptoms
5
. 
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Table 1: Demographics of included studies 
 
Study Type # 
pts 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventions 
Jones
4
, 
2005 
 
Double 
blind with 
flexible 
dosing 
RCT 
30 21-40 Gestational age 
of 16-30 wks; 
opioid 
dependence 
with request 
for 
maintenance 
therapy; recent 
opioid use; 
opiate positive 
urine 
Urine positive 
for 
undocumented 
methadone; 
ETOH 
abuse/dependen
ce; use of 
benzos; serious 
concurrent 
medical illness; 
pre-term labor; 
fetal 
malformation; 
HIV +; sickle 
cell trait 
10 Randomized to 
receive SL 
buprenorphine 
HCL (4-24 
mg) or 
methadone 
HCL (20-100 
mg) 
Fischer
3
, 
2006 
 
Double 
blind with 
flexible 
dosing 
RCT 
18 Age ≥ 
18 
Opioid 
dependence; 
gestational age 
of 24-29 wks; 
opioid positive 
urine, but neg 
for benzos and 
methadone; 
negative 
ETOH breath 
test 
Severe somatic 
or other 
psychiatric 
distress; high 
risk pregnancies 
4 Randomized to 
receive 
buprenorphine 
(8-24 mg) or 
methadone 
(40-100 mg) 
Kakko
5
, 
2008 
 
Case series 65 Age ≥ 
18 
Buprenorphine 
arm: one year 
of documented 
opioid 
dependence; 
methadone 
arm: four years 
of documented 
opioid 
dependence 
Less than one 
year of 
documented 
opioid use 
(buprenorphine 
arm); less than 
four years of 
documented 
opioid 
dependence 
(methadone 
arm) 
0  Buprenorphine 
maintenance to 
methadone 
maintenance 
during 
pregnancy 
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RESULTS 
 The studies performed by Fischer et al and Jones el al were RCTs that utilized double 
blind, double dummy with flexible dosing methods in which the neonates were observed in-
patient under blinded conditions regarding the mothers treatment.  Kakko et al utilized data that 
was analyzed retrospectively, as it was a case series.  Results reported by Fischer et al were 
presented as continuous data that could not be converted to dichotomous data, where as results 
reported by Jones et al and Kakko et al were presented in dichotomous format. 
 Fischer et al did not report sufficient information to convert data to dichotomous format.  
The authors did report the following; the mean duration of treatment for neonates exposed to 
buprenorphine was 4.8 days and neonates exposed to methadone was 5.3 days, with a reported p-
value of 0.766 (Table 2).  Additionally, infants exposed to methadone required treatment for 
NAS approximately 12 hours before those exposed to buprenorphine, with a reported p-value of 
0.537.  The amount of medication needed to treat symptoms of NAS did not vary widely as those 
exposed to buprenorphine required 2.00 mg (± 2.00) of morphine where as those exposed to 
methadone required 2.71 mg (±1.68) of morphine, with a reported p-value of 0.640 (Table 2).  
The authors also found that neonates from mothers with high rates of cigarette use (more than 10 
cigarettes per day) had higher Finnegan scores than those who smoked less than 10 cigarettes per 
day.  At the time of delivery the mean dose of buprenorphine given to subjects during pregnancy 
was 13.5 mg and the mean dose of methadone was 47.5 mg (Table 4). 
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Table 2: Reported data by Fischer et al. 
 
Data Reported Buprenorphine 
group 
Methadone group p-value 
Mean duration of 
treatment (days) 
4.8 days 5.3 days 0.766 
Amount of medication 
needed to treat (mg of 
morphine) 
2.00 mg (± 2.00) 2.71 mg (± 1.68) 0.640 
 
 Jones et al reported that 20% of neonates exposed to buprenorphine required treatment 
for NAS whereas 45% of infants exposed to methadone required treatment, with a reported p-
value of 0.23.  The RRR and ARR were calculated to be 56% and 25.5% respectively.  NNT was 
-4, therefore for every 4 patients exposed to buprenorphine in utero there was one fewer 
incidence of NAS compared to the group exposed to methadone (Table 3).  At the time of 
delivery the average dose of buprenorphine given to subjects during the pregnancy was 18.7 mg 
and the average dose of methadone was 79.1 mg (Table 4). 
 Kakko et al reported that 40.4% of neonates exposed to buprenorphine exhibited 
symptoms of NAS, whereas 77.8% of those exposed to methadone did, with a calculated p-value 
of 0.0008.  RRR and ARR were calculated to be 48% and 37.4% respectively.  NNT was -3, 
therefore for every 3 patients exposed to buprenorphine there was one fewer incidence of NAS 
than in the group exposed to methadone (Table 3).  Kakko et al also reported that 14.9% of 
infants exposed to buprenorphine required treatment for NAS symptoms, where as 52.8% of 
those exposed to methadone did, with a p-value of 0.0004.  Additionally the total hospital stay 
was significantly longer in infants exposed to methadone (19.7 ± 18.8 days) compared to infants 
exposed to buprenorphine (9.4 ± 8.4 days), with a reported p-value of 0.0009.  At the time of 
birth, the mean amount of buprenorphine given to subjects during the pregnancy was 15.4 mg (± 
6.4) and the mean amount of morphine was 71.3 mg (± 27.3) (Table 4). 
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Table 3-Efficacy of buprenorphine in prevention of NAS (Jones et al & Kakko et al) 
 
Study CER EER RRR ARR p-value NNT 
Jones
4
 45.5% 20% -56% -25.5% 0.23 -4 
Kakko
5 
77.8% 40.4% -48% -37.4% 0.0008 -3 
 
Table 4-Mean Doses of Maternal Buprenorphine and Methadone 
 
Study Mean Dose of 
Buprenorphine (mg) 
Mean Dose of Methadone 
(mg) 
Fischer
3 
13.5 47.5 
Jones
4 
18.7 79.1 
Kakko
5 
15.4 (± 6.4) 71.3 (± 27.3) 
 
The included studies required a maternal history of opioid dependence as defined by the 
DSM-IV.  Participants in the study performed by Jones et al were randomized to receive 
sublingual buprenorphine 4-24 mg or methadone HCL 20-100 mg, which was titrated based on 
each individual’s signs and symptoms of withdrawal.  The study began with 30 participants, with 
10 women withdrawing, reasons included a medical condition, missed consecutive dosing days 
and an elective withdrawal. Similarly, participants in the study performed by Fischer et al were 
randomized to receive 8-24 mg of buprenorphine or 40-100 mg of methadone; they began with 
18 participants and had 4 withdrawals.  Reasons for withdrawal included two participants who 
were non compliant with scheduled visits, one stillbirth and one late abortion. Kakko et al 
performed a case series, therefore retrospectively analyzed 39 pregnant women who were 
managed using buprenorphine therapy and 26 pregnant women who were managed using 
methadone therapy.   
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 Co-morbid drug use was a common external factor in all three studies.  Kakko et al noted 
that 15 out of 47 participants in the buprenorphine group utilized illicit substances (either opiates 
or cannibis) and 17 of the 35 participants receiving methadone did.  Fischer et al reported at 14 
weeks 66% of mothers were positive for opiates, 48% were positive for cocaine and 16% were 
positive for benzodiazepines; however between 36-38 weeks all participants were opioid 
positive, but negative for cocaine and benzodiazepines.  Jones et al reported of those treated with 
buprenorphine 16.7% tested positive for opiates, 15.2% were positive for cocaine and 2.5% were 
positive for benzodiazepines at the time of birth.  Similarly, of those treated with morphine 
15.6% tested positive for opiates, 11.2% were positive cocaine, 0.4% were positive for 
benzodiazepines and 7.5% were positive for marijuana.  
DISCUSSION 
 Buprenorphine is FDA approved for the treatment of opiate dependence by preventing 
symptoms of withdrawal.  It is a partial agonist at the mu-opioid receptor and an antagonist at the 
kappa-opioid receptor and is a Schedule III narcotic
4
.  It is available in two formulations; 
Suboxone, which contains buprenorphine HCL and naloxone HCL and Subutex, which contain 
only buprenorphine HCL.  Currently buprenorphine is classified under pregnancy category C and 
is indicated during pregnancy only if the benefit justifies the potential risk to the fetus
4
.  Caution 
must be used when taking buprenorphine, as respiratory depression and death are potential 
adverse effects
4
.   
 The study by Kakko et al appeared to show a significant relationship between maternal 
buprenorphine use and a decrease in NAS symptoms (p=0.0008).  While these findings are 
clinically significant, one must use caution when interpreting these results due to the nature of 
the study (case series).  The two RCTs reviewed (Fischer et al and Jones et al) did not show a 
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clinically significant correlation between maternal buprenorphine use and a decrease in NAS 
symptoms.  Each of the studies included did have limitations.  The study performed by Kakko et 
al was limited as it was a case series, the study was non-randomized, duration of previous drug 
abuse was unknown and NAS scoring and assessments were not blind.  While the study by Jones 
et al was a RCT, it also had its limitations.  The study included only 30 participants with 10 
withdrawals and women were not enrolled into the study until 16 weeks gestational age therefore 
generalizations cannot be made regarding neonates conceived during already established 
maintenance therapy.  Fischer et al similarly only had 18 participants with 4 withdrawals and 
concurrent tobacco use may have affected outcomes.   All of the studies were limited by illicit 
drug use. 
CONCLUSION 
 The studies reviewed demonstrate that maternal buprenorphine use during pregnancy is 
not effective in reducing signs and symptoms of NAS when compared to methadone.  While 
Kakko et al did find a significant relationship these findings were limited due to the nature of the 
study (case series), the results would have been more significant if it had been a RCT.  The two 
RCTs included did not find a significant correlation between maternal buprenorphine use and a 
reduction in NAS symptoms.  Future studies are warranted to evaluate the efficacy of 
buprenorphine and NAS.  Efforts should be made to reduce outside influences such as illicit drug 
use and tobacco use.  Larger sample sizes are needed and ideally treatment with either 
buprenorphine or methadone should be started prior to conception.  Additionally, efforts should 
also be made to standardize dosing of buprenorphine and methadone among participants.
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